25. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for covid – 19 interim solidarity trial results. New England Journal of Medicine 2021; 384:497- 511 https://pubmed.ncbi.nlm.nih.gov/33264556/ 26. RECOVERY Collaborative Group. Effects of hydroxychloroquine in hospitalized patients with COVID – 19. New England Journal of Medicine. 2020; 383: 2030 - 2040 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556338/pdf/NEJMoa2022926.pd f 27. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for the prevention and treatment of COVID – 19. Cochrane Library 2021 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/ep df/full 28. Skipper C, Pastick K, Engen N. Hydroxychloroquine in nonhospitalized adults with early COVID – 19 a randomized trial. Annals of Internal Medicine 2020; 173: 623- 631. doi: 10.7326/M20-4207. https://pubmed.ncbi.nlm.nih.gov/32673060/ 29. Cavalcanti, Zampieri F, Rosa R. Hydroxychloroquine with or without azithromycin in mild to moderate COVID 19. New England Journal of Medicine 2020; 383: 2041 – 2052 doi:10.1056/NEJMoa2019014 30. Johnston C, Brown E, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS – CoV-2 infection among high – risk outpatient adults. A randomized trial. EClinicalMedicine 2021 33:100773. Doi:10.1016/j.eclinm.2021.100773 31. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clinical Infectious Disease . 2021 6: e4073-e4081. doi: 10.1093/cid/ciaa1009. PMID: 32674126; PMCID: PMC7454406.
Anchorlines, June/July 2022
12
Made with FlippingBook - professional solution for displaying marketing and sales documents online